<DOC>
	<DOCNO>NCT00122460</DOCNO>
	<brief_summary>The purpose trial investigate efficacy cetuximab combination chemotherapy comparison chemotherapy alone patient recurrent metastatic head neck cancer . Overall survival take primary measure efficacy .</brief_summary>
	<brief_title>Cetuximab ( Erbitux ) Combination With Cisplatin Carboplatin 5-Fluorouracil First Line Treatment Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma Head Neck ( EXTREME )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis squamous cell carcinoma head neck ( SCCHN ) Recurrent and/or metastatic SCCHN , suitable local therapy Prior systemic chemotherapy , except give part multimodal treatment locally advanced disease complete 6 month prior study entry Surgery ( exclude prior diagnostic biopsy ) , irradiation within 4 week study entry Nasopharyngeal carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Head Neck Cancer</keyword>
</DOC>